Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Given Consensus Rating of “Hold” by Brokerages

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has received a consensus rating of “Hold” from the twenty-two brokerages that are presently covering the stock, Marketbeat.com reports. Three research analysts have rated the stock with a sell rating, ten have assigned a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $106.20.

Several research analysts have issued reports on ZBH shares. Wells Fargo & Company upped their price objective on Zimmer Biomet from $93.00 to $98.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 11th. UBS Group reaffirmed a “sell” rating and set a $89.00 price target on shares of Zimmer Biomet in a research note on Wednesday, February 11th. William Blair began coverage on Zimmer Biomet in a research report on Friday, February 20th. They issued a “market perform” rating for the company. Canaccord Genuity Group dropped their price objective on Zimmer Biomet from $101.00 to $93.00 and set a “hold” rating for the company in a report on Monday, November 10th. Finally, Evercore raised shares of Zimmer Biomet from an “in-line” rating to an “outperform” rating and raised their target price for the company from $94.00 to $120.00 in a research note on Monday, January 5th.

Zimmer Biomet Price Performance

NYSE:ZBH opened at $93.33 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.98 and a debt-to-equity ratio of 0.55. The firm has a market cap of $18.26 billion, a PE ratio of 26.36, a price-to-earnings-growth ratio of 1.96 and a beta of 0.58. Zimmer Biomet has a 12 month low of $84.59 and a 12 month high of $114.44. The company’s 50-day moving average price is $92.06 and its two-hundred day moving average price is $95.79.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 EPS for the quarter, topping the consensus estimate of $2.38 by $0.04. The company had revenue of $2.24 billion for the quarter, compared to analysts’ expectations of $2.22 billion. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.The business’s revenue for the quarter was up 10.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.31 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. On average, equities analysts anticipate that Zimmer Biomet will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date is Tuesday, March 31st. Zimmer Biomet’s dividend payout ratio (DPR) is currently 27.12%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Key Financial Inc boosted its position in shares of Zimmer Biomet by 164.6% during the third quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 163 shares during the period. DV Equities LLC bought a new stake in Zimmer Biomet in the 4th quarter valued at approximately $25,000. Cullen Frost Bankers Inc. lifted its stake in Zimmer Biomet by 66.7% in the 3rd quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 116 shares in the last quarter. Root Financial Partners LLC acquired a new position in Zimmer Biomet during the 3rd quarter worth approximately $31,000. Finally, Cary Street Partners Investment Advisory LLC grew its stake in shares of Zimmer Biomet by 83.7% during the 2nd quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider’s stock worth $30,000 after acquiring an additional 149 shares in the last quarter. 88.89% of the stock is currently owned by institutional investors.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.